Time course of imaging changes of GBM during extended bevacizumab treatment

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Neuro-Oncology

• Publication date

  2008-04-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11060-008-9573-xPMID 18389177
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

  2007cited by this paper
• Effect of bevacizumab on radiation necrosis of the brain.

  2007cited by this paper
• VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.

  2007influential reference
• Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2

  2007cited by this paper
• MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy

  2006influential reference
• Inhibition of hypoxia inducible factor-1α (HIF-1α) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas

  2006cited by this paper
• Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods.

  2006cited by this paper
• Pharmacokinetics of a novel formulation of ivermectin after administration to goats.

  2006cited by this paper
• Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas.

  2006cited by this paper
• 'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis

  2006cited by this paper
• Expression of VEGF and its receptors in different brain tumors

  2005cited by this paper
• MR imaging correlates of survival in patients with high-grade gliomas.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

  2005cited by this paper
• Hypoxia‐inducible factor 1α/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis

  2004cited by this paper
• Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression

  2004cited by this paper
• The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival.

  2003cited by this paper
• Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every‐3‐week regimen

  2003cited by this paper
• Evaluation of response: new and standard criteria.

  2002cited by this paper
• Comparison of diameter and perimeter methods for tumor volume calculation.

  2001cited by this paper
• A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

  1999cited by this paper
• Glioblastoma multiforme: radiologic-pathologic correlation.

  1996cited by this paper

• Emerging Therapies for Glioblastoma

  2024cites this paper
• Rules-based Volumetric Segmentation of Multiparametric MRI for Response Assessment in Recurrent High-Grade Glioma

  2023cites this paper
• Dose-dependent efficacy of bevacizumab in recurrent glioblastoma

  2023cites this paper
• Advanced Magnetic Resonance Imaging in Glioblastoma: A Advanced Magnetic Resonance Imaging in Glioblastoma: A Review Review

  2022cites this paper
• The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab

  2022cites this paper
• Longitudinal structural and perfusion MRI enhanced by machine learning outperforms standalone modalities and radiological expertise in high-grade glioma surveillance

  2021cites this paper
• Imaging acute effects of bevacizumab on tumor vascular kinetics in a preclinical orthotopic model of U251 glioma

  2021cites this paper
• Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: a systematic review and meta-analysis of outcome rates.

  2020cites this paper
• Decision making in surveillance of high-grade gliomas using perfusion MRI as adjunct to conventional MRI and artificial intelligence.

  2019cites this paper
• Chapter 3 . 2 Comparison of 2 D ( RANO ) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab – a report from the BELOB trial

  2019cites this paper
• Contrast-Enhanced T1-Weighted Digital Subtraction for Increased Lesion Conspicuity and Quantifying Treatment Response in Malignant Gliomas

  2019cites this paper
• Newly Diagnosed Glioblastoma: A Review on Clinical Management.

  2019cites this paper
• Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?

  2018cites this paper
• Characterization of multi-cellular dynamics of angiogenesis and vascular remodelling by intravital imaging of the wounded mouse cornea

  2018cites this paper
• Preclinical MRI: Studies of the irradiated brain.

  2018cites this paper
• Advanced magnetic resonance imaging in glioblastoma: a review.

  2017cites this paper
• Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.

  2017cites this paper
• Recurring Glioblastoma: A Case for Reoperation?

  2017cites this paper
• Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial

  2017cites this paper
• Neurologic Emergencies in the Patients With Cancer

  2017cites this paper
• Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

  2017cites this paper
• Disease progression patterns of bevacizumab responders with recurrent malignant gliomas

  2017cites this paper
• Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials

  2017cites this paper
• RANO Criteria: Application to Response Assessment in Clinical Trials

  2016cites this paper
• Cost-Effectiveness Of Bevacizumab Concomitant With The Standard Of Therapy For Newly Diagnosed Glioblastoma

  2016cites this paper
• Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review

  2016cites this paper
• Glucocorticoids in the management of peritumoral brain edema: a review of molecular mechanisms

  2016cites this paper
• Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab.

  2016cites this paper
• Disorders of Vascular Permeability.

  2016cites this paper
• CGCG clinical practice guidelines for the management of adult diffuse gliomas.

  2016cites this paper
• Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials1

  2015cites this paper
• Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.

  2015cites this paper
• Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?

  2015cites this paper
• Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas

  2015cites this paper
• Improved visibility of brain tumors in synthetic MP‐RAGE anatomies with pure T1 weighting

  2015cites this paper
• Title Advanced MR Imaging of Gliomas : An Update Permalink

  2014cites this paper
• Connexin hemichannel induced vascular leak suggests a new paradigm for cancer therapy

  2014cites this paper
• T11TS inhibits glioma angiogenesis by modulation of MMPs, TIMPs, with related integrin αv and TGF-β1 expressions

  2014cites this paper
• Pros and cons of current brain tumor imaging.

  2014cites this paper
• Anti-VEGF Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain

  2014cites this paper
• Medical Computer Vision. Large Data in Medical Imaging: Third International MICCAI Workshop, MCV 2013, Nagoya, Japan, September 26, 2013, Revised Selected Papers

  2014influential citation
• Cancer Therapy : Preclinical Anti-VEGF AntibodiesMitigate the Development of Radiation Necrosis in Mouse Brain

  2014cites this paper
• Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab

  2014cites this paper
• Update on Anti-angiogenic Treatment for Malignant Gliomas

  2014cites this paper
• Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

  2014cites this paper
• Semiautomatic segmentation and follow-up of multicomponent low-grade tumors in longitudinal brain MRI studies.

  2014cites this paper
• A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma.

  2014cites this paper
• Update on the use of angiogenesis inhibitors in adult patients with brain tumors.

  2014cites this paper
• Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II study

  2014cites this paper
• Impact of perfusion map analysis on early survival prediction accuracy in glioma patients.

  2013cites this paper
• Advanced MR Imaging of Gliomas: An Update

  2013cites this paper
• Integrated Spatio-Temporal Segmentation of Longitudinal Brain Tumor Imaging Studies

  2013cites this paper
• Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.

  2013cites this paper
• MRI Characterization of Radiation Necrosis in an Animal Model: Time to Onset, Progression, and Therapeutic Response

  2013cites this paper
• Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab.

  2013cites this paper
• T11TS impedes glioma angiogenesis by inhibiting VEGF signaling and pro-survival PI3K/Akt/eNOS pathway with concomitant upregulation of PTEN in brain endothelial cells

  2013cites this paper
• Glioblastoma multiforméban szenvedõ betegek célzott terápiás kezelésével szerzett tapasztalataink

  2013cites this paper
• Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach

  2013cites this paper
• Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma

  2013cites this paper
• Bevacizumab for the treatment of glioblastoma

  2013cites this paper
• Glioblastomas: are individual therapies required for individual tumors?

  2013cites this paper
• Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway

  2013cites this paper
• Automatic multi-modal MR tissue classification for the assessment of response to bevacizumab in patients with glioblastoma.

  2013cites this paper
• Therapeutic brain cancer targeting by gene therapy and immunomodulation

  2012cites this paper
• Bevacizumab and etoposide combination chemotherapy in patients with recurrent malignant gliomas who failed bevacizumab

  2012cites this paper
• Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators

  2012cites this paper
• Prediction of Glioblastoma Multiform Response to Bevacizumab Treatment Using Multi-Parametric MRI

  2012cites this paper
• Therapeutic brain cancer targeting by gene therapy and immunomodulation : a translational study

  2012influential citation
• Imaging the Postoperative Brain

  2012cites this paper
• Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.

  2012cites this paper
• Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management.

  2012cites this paper
• Efficacy and safety of bevacizumab in glioblastomas.

  2012cites this paper
• Vascular endothelial growth factor-induced permeability in the pathogenesis of cardiac allograft vasculopathy

  2011cites this paper
• Monitoring Radiographic Brain Tumor Progression

  2011cites this paper
• Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure

  2011cites this paper
• Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab

  2011cites this paper
• Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma.

  2011cites this paper
• Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab

  2011cites this paper
• Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas

  2011cites this paper
• A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors

  2011cites this paper
• Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis.

  2011cites this paper
• Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.

  2011cites this paper
• Principles of Clinical Trial Design and Response Assessment

  2011cites this paper
• Brain Tumor Outcome Studies

  2011cites this paper
• Effekte einer anti-VEGF-A-Therapie (Bevacizumab) auf humane cerebrale Endothelzellen sowie Tumor- und Endothelzellen in humanen Gliomen

  2011cites this paper
• Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema

  2011cites this paper
• P/H MRSI and quantitative magnetic resonance imaging study

  2011cites this paper
• The paradoxical effect of bevacizumab in the therapy of malignant gliomas

  2011cites this paper
• Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy

  2010cites this paper
• Apparent Diffusion and Fractional Anisotropy of Diffuse Intrinsic Brain Stem Gliomas

  2010cites this paper
• Role of bevacizumab therapy in the management of glioblastoma

  2010cites this paper
• Molecular Therapeutic Targets for Glioma Angiogenesis

  2010cites this paper
• Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity

  2010cites this paper
• Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab

  2010cites this paper
• Could Be Systems-Directed Therapy Approaches Promising in Glioblastoma Patients?

  2010cites this paper
• Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

  2010cites this paper
• Balloon-Assisted Superselective Intra-Arterial Cerebral Infusion of Bevacizumab for Malignant Brainstem Glioma

  2010cites this paper
• Newly Diagnosed High-Grade Gliomas

  2010cites this paper
• Vascular endothelial growth factors and vascular permeability

  2010cites this paper
• Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker

  2010cites this paper